January 29, 2013 - Myeloma - The Latest on Research and Treatment from the American Society of Hematology (ASH®) Annual Meeting
Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.
Date: January 29, 2013
Time: 12:00 p.m. - 1:30 p.m. ET
Location: Telephone/Web
Read: Myeloma News | Transcript
Download: Program Slides
Listen: Presentation | Q&A Session
Access: Virtual Lecture
Topics Covered
- Updates about current and emerging myeloma treatment options
- Updates in myeloma maintenance therapy
- The role of clinical trials in the advancement of myeloma treatment
- Advances in myeloma treatment side effects management
Speaker
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
Questions Asked by the Myeloma Community
- Is there a new study about when treatment should begin for patients diagnosed with multiple myeloma in the smoldering stage?
- If the level of the M-spike protein is not observable, does this indicate myeloma is in remission?
- Do steroid medications and spinal injections affect bone marrow and blood work results for the M-protein?
- What are the chances of pomalidomide (Pomalyst®) being tolerated, if thalidomide (Thalomid®) was not?
- Please comment on T cell and T cell receptor therapy in myeloma. For example, Carl June at Penn.
- Is there a limit to the number of transplants that a patient can have?
- Please discuss maintenance therapy post-stem cell transplant, including when there is a complete response.
- Is it beneficial to reinstate lenalidomide (Revlimid®) maintenance therapy that was started after transplant and was discontinued for fear of getting a secondary cancer?
- If taking lenalidomide (Revlimid®) 25 milligrams, as maintenance, can the dose be decreased? Or, is it safe to stay on this dose indefinitely?
- How do treatments for Myeloma change when the patient also has primary amyloidosis?
- Is central nervous system neuropathy a side effect of bortezomib (Velcade®)? If so, what remedies are effective?
- What do you recommend for a patient with nerve pain following shingles and for preventing shingles in patients with myeloma?
- Are there benefits of utilizing complementary therapies such as acupuncture to help with pain?
- Please comment on the use of curcumin for smoldering myeloma.
Sponsors and Supporters
This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals, Inc.
This program is not sponsored, sanctioned by, or part of the 54th Annual Meeting of the American Society of Hematology (ASH®)
